Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 10/20 | 0.62 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | STAT1 | P42224 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | SMO | Q99835 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2800334 | 0.88 | CAPN1 (0.70) | CAPN1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2799610 | 0.86 | CAPN1 (0.67) | CAPN1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2801013 | 0.85 | CAPN1 (0.75) | CAPN1 | |
| SCHEMBL2800813 | 0.83 | CAPN1 (0.67) | CAPN1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2802814 | 0.81 | CAPN1 (0.67) | CAPN1ALDH1A1MEN1HPGDKMT2A | |
| SCHEMBL2801286 | 0.79 | CAPN1 (0.75) | CAPN1 | |
| SCHEMBL2799591 | 0.77 | CAPN1 (1.00) | CAPN1 | |
| SCHEMBL1990682 | 0.77 | CAPN1 (0.73) | CAPN1 | |
| SCHEMBL2799523 | 0.76 | CAPN1 (0.67) | CAPN1SMN1; SMN2ALDH1A1MEN1HPGD | |
| SCHEMBL20027515 | 0.75 | BACE1 (0.37) | CAPN1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567325-B2 | Carboxamide compounds and their use as calpain inhibitors | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-02-14 | — | — | US | disclosed |
| US-20150045394-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-02-12 | — | — | US | disclosed |
| US-8906941-B2 | Carboxamide compounds and their use as calpain inhibitors | ABBVIE INC. (US) | 2014-12-09 | — | — | US | disclosed |
| EP-2398783-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | Abbott GmbH & Co. KG (DE) | 2011-12-28 | — | — | EP | disclosed |
| US-20100216844-A1 | Carboxamide compounds and their use as calpain inhibitors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-08-26 | — | — | US | disclosed |
| WO-2010094755-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045394-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS | CAMK4, CAMK2A, CAMK2B | CAPN1 4/4885PIN1 1676/4885NPC1 4325/4885 |
| US-20100216844-A1 | Carboxamide compounds and their use as calpain inhibitors | CAMK4, CAMK2A, CAMK2B | CAPN1 4/4885PIN1 1732/4885NPC1 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.